For rats, glomerular filtration rate (GFR) and its relative GFR (ratio to normal GFR 0 ) were estimated in order to classify their chronic kidney disease (CKD) into 5 stages like those in humans. The adenine-loaded rats, which were used to show the intrinsic antioxidant and creatinine (Cr) metabolite, NZ-419 (5-hydroxy-1-methylimidazolidine-2,4-dione), when taken orally, prevented the progression of chronic renal failure (CRF), were used as a model to reach the severest stage 5. In this report, we show that, by using both a tubular lesion and a glomerular lesion models (adenine-loaded and 5/6 nephrectomized rats, respectively), peroral NZ-419 might be a common tool to prevent the progression of CRF at CKD stages 3 and 4 under the condition that most rats in the control group still remained at stage 4 (0.15Ͻ ϽGFR/GFR 0 Ͻ Ͻ0.29) at the last. At the minimum effective dose (MED: 100 mg/kg/d) of NZ-419 in adenine-loaded rats, serum Cr and all oxidative stress markers were ameliorated. Two doses (80, 160 mg/kg/d), at around the MED, used for 5/6 nephrectomized rats with a similar CRF severity, gave significant inhibitory effects against the increases in blood urea nitrogen, decreases in renal blood flow and renal plasma flow, and nephrotic syndrome. Oxidative stress markers, the urinary methylguanidine and serum albumin level, were significantly ameliorated.
Once the irreversible process of chronic renal failure (CRF) is established, from whatever causative diseases, a progressive course follows ultimately leading to the cessation of renal function and end-stage renal disease (ESRD). Recently the concept of chronic kidney diseases (CKD) and its classification into five stages has become popular among medical practitioners since 2002 (Table 1) . 1) Treatments of patients have been indicated to be different between stage 1 or 2 and 3, 4 or 5: at the former stage, 1 or 2, kidney damage is important but decrease in glomerular filtration rate (GFR) is still not practically crucial, but at the latter stage, 3, 4 or 5, decrease in GFR is serious and CRF cannot be ignored, 1) as hydroxyl radicals increase markedly.
2) Effective treatments of CRF patients or CKD patients at stages 3, 4 and 5 before ESRD have been widely recognized as essential and urgent targets. 1) In our previous paper, 3) we reported for the first time that an intrinsic antioxidant compound could prevent the initiation and/or progression of CRF: the compound investigated was NZ-419 (5-hydroxy-1-methylimidazolidine-2,4-dione, 5-hydroxy-1-methylhydantoin: HMH, CAS: 84210-26-4), [4] [5] [6] [7] [8] [9] a creatinine (Cr) metabolite that prevented the initiation and/or progression of adenine-induced CRF. We chose CRF or CKD at stages equivalent to human stages 3, 4 and 5, where hydroxyl radicals are over-produced, 2, 10) as one of the targets aims, 3, 11, 12) because NZ-419 had been shown to be a hydroxyl radical scavenger. 11, 12) Meanwhile, since there is a hypothesis that oxidative stress might be a common key factor in the progression of CRF induced by several different causes, antioxidants might inhibit the progression of CRF regardless of its causes. 3) In order to assess whether NZ-419 could be used as a common treatment for CRF at CKD stages equivalent to human ones, 3, 4 and 5, its effect on CRF with other causes must be also investigated. Since adenine-induced CRF rats 13, 14) have been shown to be a tubular lesion model, (as a glomerular lesion model) an additional model of 5/6 nephrectomized rats 15) was used together with the adenine-loaded rats in this study. Because NZ-419 might not be an agent to delete uremic toxins and CKD stage 5 might be too late to be treated with NZ-419, we thought stages 3 and 4 might be the best stages for treatment timing for CKD. And so we chose the conditions which might not lead most rats to stage 5. Firstly, we investigated the minimum effective dose (MED) of NZ-419 in adenine-loaded rats, and then its efficacy in nephrectomized rats at doses around the MED.
The hyperfiltration theory states that, as nephrons are gradually lost in renal failure, the remaining nephrons become hypertrophied to compensate for the loss of renal function, and hyperfiltration in these remaining nephrons leads to further nephron losses. 16) These nephron losses induce a reduction of renal function such as via progressive proteinuria and a declining GFR. Nephron loss is caused by glomerulosclerosis, tubulointerstitial fibrosis, the loss of glomerular cells, and tubular atrophy. 17) Now some effective treatments including dietary control, drug therapy with a spherical carbonaceous absorbent, and anti-hypertensive drugs including ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin receptor blockades) were available to inhibit the progression of CKD and CRF, but these were still not effective enough. Therefore, the development of new drugs that prevent the progression of CKD and CRF with a new mechanism is still an urgent requirement.
Although the mechanism leading to the progression of CKD and CRF has not yet been fully elucidated, other common mechanisms have been considered. Among them, oxidative stress-related mechanisms have been widely studied, as we cited in our previous paper.
3) Antioxidants have shown ef- 18, 19) As candidates, we have already reported that tannins, antioxidants in green tea and crude drug etc., showed inhibitory effects on the progression of CRF in adenine-loaded and nephrectomized rats. [20] [21] [22] In our previous paper, 3) we reported that NZ-419 could be one such safe candidate because crucial side effects were not observed at doses less than 1000 mg/kg/d.
MATERIALS AND METHODS

Estimation of GFR for Rats
Clinically, GFR and Cr clearance (C Cr ) have been successively estimated from the corresponding serum Cr (sCr) value, 1) if we consider the coefficient for gender, race, age, and body surface area or weight. Since, in our reported papers, [23] [24] [25] only male Wistar rats with a similar age were used, a simple correlation equation between the ratio C Cr /C Cr0 (C Cr0 : C Cr of normal rats) and sCr was obtained using the reported corresponding mean values of various groups with a different renal function. [23] [24] [25] We hypothesized that GFR/GFR 0 as well as GFR, GFR 0 (GFR of normal rats) is nearly equal to corresponding C Cr /C Cr0 , C Cr , and C Cr0 , respectively.
We have already measured six kinds of values at the same time: values of GFR, renal plasma flow (RPF) and renal blood flow (RBF) for CRF rats plus those of normal rats (GFR 0 , RPF 0 and RBF 0 , respectively). 23, 24) We also obtained correlations between relative renal functions such as GFR/GFR 0 and RPF/RPF 0 or RBF/RBF 0 , using the reported mean values of various groups with different renal functions in our paper.
After GFR/GFR 0 was estimated by three methods mentioned above via sCr, RPF/RPF 0 or RBF/RBF 0 , since rat GFR 0 has been reported to be ca. 0.55 ml/min/kg, 23) estimated GFR (eGFR) could be calculated from GFR/GFR 0 .
Comparison of Renal Function-Related Parameters between Animals and Clinical Cases Clinically, CKD patients are now classified into five stages using the GFR (Table  1) . 1) Stages of CRF patients are shown to be 3, 4, or 5: eGFR of these are 30-59, 15-29, or Ͻ15 ml/min/1.73 cm 3 , respectively. Since the clinical eGFR 0 has been shown to be ca. 100 ml/min/1.73 cm 3 , 26) the relative renal function, eGFR/ eGFR 0 , of patients in stages 3, 4, and 5 would be 0.30-0.59, 0.15-0.29, or Ͻ0.15, respectively. So, we divided rats with similar stages to humans using the relative renal function, GFR/GFR 0 (Table 1) .
Animals and Chemicals The Guidelines for Animal Experimentation, approved by the University of Toyama, were followed in these experiments. Male Wistar rats (ca. 200-210 g), obtained from Japan SLC, Inc. (Hamamatsu, Japan), were used. They were maintained at a constant humidity (ca. 60%) and temperature (ca. 23°C) with a light/dark cycle of 12 h. NZ-419 was prepared in the Institute of Bio-Active Science (IBAS: Nippon-Zoki, Hyogo, Japan). Other reagents were of an analytically pure or HPLC grade.
Experiment Using Adenine-Loaded CRF Rats. (A) Experimental Design Rats were allowed an adaptation period of several days, during which time they were fed a commercial feed (type CE-2, CLEA Japan Inc., Tokyo, Japan). They were then fed by adopting a pair-feeding schedule on an 18% casein diet containing 0.75% adenine, which experimentally induced renal failure in the animals. 13) During the adenine-feeding period, an aqueous solution of NZ-419 (25, 50, 100 mg/kg) was administered orally for 20 d in drinking water, while control rats received tap water.
3) (B) Determination of Serum Components Urea nitrogen, total protein, albumin, inorganic phosphate, and calcium were determined using commercial reagents (BUN Kainos, from Kainos Laboratories, Inc., Tokyo, Japan; A/G B-Test Wako, Phosphor B-Test Wako, and Calcium C-Test Wako, from Wako Pure Chemical Industries, Ltd., Osaka, Japan). Concentrations of Cr, methylguanidine (MG), and guanidinosuccinic acid (GSA) were analyzed with a guanidino-compound analyzing system (Japan Spectroscopic Co., Tokyo, Japan) by HPLC using the fluorogenic reagent 9,10-phenanthrenequinone.
(C) Determination of MED Among the MED for parameters measured, the MED of sCr was chosen to be the MED for this adenine-loaded model.
Experiment Using 5/6 Nephrectomized Rats. (A) Experimental Design
Rats weighing about 200 g were resectioned leaving of 2/3 of the left kidney and total excision of the right kidney with an inter-operative interval of 10 to 14 d. The blood urea nitrogen level of the rats was determined after their recovery from the operation, and they were divided into three groups to avoid any inter-group difference in the blood urea nitrogen level. The first group was given water, while the other two groups were administered orally with NZ-419 at 80 or 160 mg/kg body weight/d in drinking water for 90 consecutive days. We chose these two doses, 80 and 160 mg/kg/d, in order to sandwich the MED (100 mg/kg/d) for the adenine-loaded model. The dose was adjusted by regulating the concentration in relation to water consumption. To ensure that the food intake was constant among the three groups, the animals were raised on a pair-feeding schedule. Blood urea nitrogen and urinary protein excretion were determined every 10 or 20, and 30 d, respectively, during the administration period. From day 89 to 90, 24-h urine was collected. On the 90th day, the renal function was evaluated as 810 Vol. 33, No. 5 shown below, and blood was collected as shown above in an adenine-loaded case. The residual kidney was completely perfused with pre-cooled saline and removed.
(B) Determination of Serum and Urine Components Urea nitrogen, total protein, albumin, Cr, MG, and GSA were determined as described above. Urinary protein was determined by the method of Lowry et al., using bovine serum albumin as a standard. 27) (C) Determination of Renal Function Parameters RPF was measured by employing the renal clearance test using a single intravenous dose of sodium para-aminohippurate as an indicator. 28) At 25 min after intravenous administration of the agent, the bladder was reflexly emptied by making each rat inhale ether for 3-5 s. The urine so voided was discarded. During the next 30 min, the urine was collected, and collection was terminated after the bladder had again been emptied reflexly by ether inhalation. Blood samples were taken from the conscious rats by heart puncture in the middle of the period used for the clearance test. para-Aminohippurate was determined by colorimetry. RBF was calculated on the basis of RPF and the hematocrit value (Ht) using the equation below. Ht was determined with an Ht measurement apparatus, model KH-120A (Kubota Co., Ltd., Tokyo, Japan): RBFϭRPF/(1ϪHt) (ml/min).
24)
(D) Histopathological Examination The other part of the renal tissues was fixed in Bouin's solution, embedded in paraffin, and cut into thin sections. These sections were stained with hematoxylin-eosin, periodic acid-Schiff, or periodic acid methenamine silver stain, and observed by optical microscopy. Mesangial proliferation was rated as normal, slight, moderate, or severe. The proportion of sclerotic lesions in each glomerulus was rated as grade 0-4, using the method of Raij et al., 29) where grade 1 represents the involvement of up to 25% of the glomerulus and grade 4 represents sclerosis of 75-100% of the glomerulus. The glomerular sclerosis index was obtained by averaging the scores for all glomeruli from each rat. The severity of tubulo-interstitial lesions was assessed according to three degrees: normal, mild, or severe. Rats from which 50 or fewer glomeruli were obtained were excluded from analysis.
Statistical Analysis Data are expressed as meansϮ S.E.M. The significance of differences between experimental groups was determined using Student's t-test and Scheffe's multiple comparison test. The level of significance was set at pϽ0.05.
RESULTS
Estimation of GFR for Rats and Comparison of Renal
Function-Related Parameters between Animals and Clinical Cases As shown in Fig. 1 , a simple correlation between C Cr /C Cr0 , thought to be nearly equal to GFR/GFR 0 , (y) and sCr (x: mg/dl) was obtained as a simple equation:
yϭ0.47/xϪ0.035 (nϭ12 groups: R 2 ϭ0.97)
If y equals 0.60, 0.30, or 0.15, x must be 0.74, 1.41, or 2.55, respectively. As shown in Table 1 , rats at stages 3, 4, and 5 might be estimated roughly to have sCr values of 0.73-1.41, 1.40-2.55, and Ͼ2.55 mg/dl, respectively.
As shown in Fig. 2 , RPF/RPF 0 and RBF/RBF 0 started decreasing at the stage 3.
The correlation between GFR/GFR 0 (y) and RPF/RPF 0 (x) was as follows:
The correlation between and GFR/GFR 0 (y) and RBF/ RBF 0 (x) was as follows:
Effective Doses of NZ-419 in Adenine-Loaded Rats The sCr level in the control rats, markedly increased beyond the normal level (0.32 mg/dl 13,14) ) but not to uremic level (3.66 mg/dl 3) ), was 2.10Ϯ0.17 mg/dl (nϭ10): the estimated GFR/GFR 0 with the Eq. 1 was 0.189 (at stage 4). The control rats gave remarkably bigger blood urea nitrogen (BUN), MG and GSA levels and smaller serum albumin (sAlb) level (BUN: 83.5Ϯ5.2 mg/dl, MG: 3.06Ϯ0.57 mg/dl, GSA: 59.67Ϯ5.85 mg/dl, sAlb: 3.39Ϯ0.04 g/dl, respectively) than reported normal levels (BUN: 12.0 mg/dl, 14) MG and GSA: not detectable, sAlb: 3.63 g/dl 12) ). However, the Ca level of the control group, 9.7Ϯ0.1 mg/dl, seemed to decrease insufficiently (normal level: 10.2 mg/dl, 13) 24-d adenine-loaded control level: 7.5 mg/dl 3) ). In contrast, the inorganic phosphate level of the control group fairly increased to 13.0Ϯ0.6 mg/dl (nϭ10) (normal level: 8.3 mg/dl: nϭ6 13) ). As shown in Fig. 3 , all values related to the renal function, except for the Ca level, in rats given with 100 mg/kg of NZ-419 were significantly better than the control levels. BUN and inorganic phosphate levels as well as MG and GSA levels showed that the dose of 50 mg/kg was also effective. Under this condition, 25 mg/kg of NZ-419 induced significantly better serum albumin level than the control level. These results suggested that the MED might be 50 or 100 mg/kg. Since sCr level is the most important one clinically evaluating a renal function, the MED was determined to be 100 mg/kg. (3) Total Protein, Albumin, and Total Cholesterol in Serum As nephrotic syndrome, not only an increase in urinary protein (as shown above) but also, in serum, a decrease in total protein and albumin (control level: 3.20Ϯ0.07 g/dl, nϭ10; reported normal level: 3.63Ϯ0.07 g/dl, nϭ6 12) ), and an increase in total cholesterol (control level; 152.9Ϯ14.9 mg/dl, nϭ10; reported normal level: 80.9Ϯ4.2 mg/dl, nϭ6 12) ) were observed at 90 d (Fig. 5B) . NZ-419 significantly inhibited each abnormality in total protein and albumin in serum at both doses (80 and 160 mg/kg of body weight/d), and total cholesterol at the higher dose.
(4) Serum and Urinary Levels of Cr, MG, and GSA As shown in Fig. 6 , the serum Cr and MG levels in the nephrectomized control rats increased to 2.23Ϯ0.17 mg/dl (nϭ10) and 2.44Ϯ0.95 mg/dl (nϭ10), respectively, at 90 d (normal rats: Cr level, 0.47 mg/dl; MG: not detectable).
14)
The relative renal function, GFR/GFR 0 was estimated from this mean sCr value using equation 1, to be 0.18 (at stage 4). Although both mean values decreased with NZ-419 treatment, a significant reduction was not observed. The urinary level of Cr in the control rats decreased, and NZ-419 increased the level but not significantly. In a case of MG, a hydroxyl radical related marker, the urinary level of the control increased to be 46.0Ϯ1.1 mg/d (nϭ8) and NZ-419 inhibited the increase in a dose-dependent manner, and the decrease at a dose of 160 mg/kg to be 39.9Ϯ1.2 mg/d (nϭ9) was significant. The serum and urinary levels of GSA in the control group increased (37.7Ϯ16.3 mg/dl (nϭ10) and 404.2Ϯ23.2 mg/dl (nϭ10), respectively), but were not much larger than those in adenine-loaded rats (serum level: 59.7Ϯ5.9 mg/dl (nϭ10). NZ-419 inhibited the increase but not significantly (Fig. 6) . creased to 3.45 and 6.05 ml/min/kg, respectively (normal level: 20.8 and 36.9 ml/min/kg, respectively). 24) Relative renal function ratio GFR/GFR 0 of the control rats was calculated to be 0.21 or 0.18, respectively, at stage 4, by using Eq. 2 and RPF/RPF 0 , 0.17 (3.45/20.8) or Eq. 3 and RBF/RBF 0 value, 0.16 (6.05/36.9). Both doses of NZ-419 (80, 160 mg/kg) significantly inhibited the decrease: corresponding RPF values were 6.43 and 6.16 ml/min/kg, respectively; RBF values were 11.48 and 11.22 ml/min/kg, respectively (Fig. 7) . Similarly, GFR/GFR 0 was calculated; for NZ-419 (80 mg/kg) rats: 0.28 or 0.26, respectively, by using Eq. 2 and RPF/RPF 0 , 0.31 (6.43/20.8) or Eq. 3 and RBF/RBF 0 0.31 (11.48/36.9), respectively; for NZ-419 (160 mg/kg) rats: 0.27 or 0.25, respectively, by using Eq. 2 and RPF/RPF 0 , 0.30 (6.16/20.8) or Eq. 3 and RBF/RBF 0 0.30 (11.22/36.9)), respectively. Ht values of the control group and NZ-419 (80, 160 mg/kg) groups were 42.5Ϯ1.0% (nϭ8), 43.7Ϯ0.8% (nϭ7), and 45.2Ϯ0.7% (nϭ5), respectively.
(6) Histological Findings The glomerular sclerosis index increased and extra-capillary lesions occurred in the control rats, as previously reported. 30, 31) NZ-419 inhibited the histological changes, but not significantly under the conditions. As illustrated in Fig. 8 , typical morphological changes, which are not seen in normal cases, were seen in the examined kidneys of the control group: glomerular changes, such as moderate mesangial proliferation, were observed as well as tubular expansion and interstitial fiblosis. In contrast, almost normal glomeruli and tubular interstitial figures were seen in the kidneys in the 160 mg NZ-419 group. The glomerular sclerosis index was reduced by 20% in both 80 and 160 mg NZ-419 groups, and the incidence of extracapillary lesions was inhibited by 38% at both doses. However, these effects under the conditions examined were not significant, as shown in Fig. 8 .
DISCUSSION
The renal function, such as GFR, RPF, and RBF, of adenine-loaded rats has been reported to decrease to less than 10% of the normal level (GFR/GFR 0 , RPF/RPF 0 or RBF/RBF 0 Ͻ0.01) after ca. 24 d of adenine loading, 24) although these abnormalities in RPF and RBF were estimated for the first time at stages equivalent to clinical CKD stages 3, 4, and 5 after the relative GFR (GFR/GFR 0 ) decreased under 0.60 (Fig. 2) . We showed in the previous paper that there was an inhibitory effect of NZ-419 against the initiation and/or progression of CRF using the same 24 d loading conditions: MED seemed 250 mg/kg/d. 3) In order to clarify the MED of NZ-419, we employed in this study a condition that is more similar to the clinical condition with 20 d of adenine loading. Under this condition stages at the last day had been thought to still remain, equivalent to clinical CKD stage 4. As we expected, most renal function-related parameters except for Ca showed abnormalities, although not as severe as in the previous experiment. In the last paper, 3) when the adenine-loading period was 24 d, the mean sCr value of the control group was 3.6 mg/dl, and so the relative renal function of GFR/GFR 0 could be estimated as 0.098: value for stage 5.
1)
In this paper, as mentioned above, after 20 d adenine-loading the mean sCr of control rats increased but still remained at the level of 2.1 mg/dl: corresponding estimated relative renal function GFR/GFR 0 was 0.189, and indicated that most rats still seemed to remain at stage 4 as we anticipated. The highest dose of NZ-419, 100 mg/kg/d, among those tested in this paper, significantly inhibited the abnormalities in the control group. Although the 50 mg/kg/d dose of NZ-419 showed the most significant efficacy, the sCr level showed a tendency to decline without significance. The clear onset of Ca abnormalities was thought to appear rather late, at the stage 5, resulting in little abnormality in the serum level in the control group, and so non-significant effect of NZ-419 on it seemed reasonable. Since the increase in MG, a hydroxyl radical related marker, in serum was significantly inhibited, the hydroxyl related radical scavenging effect played an important role in the beneficial effect of NZ-419.
3) As explained above, determination of not only the MED (at 100 mg/kg/d) for adenine loaded rats but also the values of two other doses (at 80 and 160 mg/kg/d) for 5/6 nephrectomized rats gave the predicted results.
In 5/6 nephrectomized rats, the blood urea nitrogen level was maintained around the initial level until 30 d, and increased until 90 d, reflecting chronic progressive uremia. The administration of NZ-419 significantly reduced the BUN level. The urinary protein level in the nephrectomized control rats increased from the initial to high levels at 60 and 90 d. The administration of NZ-419 significantly reduced the increase in urinary protein. On the other hand, the renal function of nephrectomized rats decreased as much as in the adenine-loaded rats in this report. The relative renal function GFR/GFR 0 was estimated from the sCr, RPF/RPF 0 , or RBF/ RBF 0 values to be 0.18, 0.21 or 0.18, respectively, which indicated that most rats in the control group still remained in stage 4. As mentioned above, decrease in GFR/GFR 0 was indicated to be inhibited with NZ-419. Although we could not confirm the significant efficacy of NZ-419 on sCr, we can conclude from the renal function-related data such as RPF, RBF, and urinary protein, that NZ-419 prevented the progression of CKD. The CKD stages remain at 3 and 4, with around 100 mg/kg/d of dose which indicated prevention of the progression of CRF in rat models.
In a tubular lesion model, where the main production site of MG is in the proximal tubule, over-production of MG is marked. Furthermore, in the adenine-loaded model, uniform CRF rats could be easily obtained and inhibition of MG production by NZ-419 could be shown clearly. In contrast, in a glomerular lesion model, after protein is leaked, reabsorption and catabolism in tubules follows, and then generation of active oxygen species in the tubules becomes apparent at stages 3, 4 and 5; and so increase in MG production is less than in a tubular lesion model. Furthermore, without a selection of rats, uniform nephrectomized rats are difficult to be obtained. Therefore, effects of test compounds on MG are likely to be more difficult to be observed.
In comparison with adenine loaded rats having the same GFR, since less hydroxyl radical level in sera has been indicated in the 5/6 nephrectomized rats, 24) lower serum level of MG with a larger standard error was observed. Therefore we could not observe significant difference, although decrease in MG was in a dose-dependent manner. In contrast, the urinary MG level of the control increased and NZ-419 decreased the level in a dose-dependent manner. The effect at a dose of 160 mg/kg was significant, probably because its standard deviation is smaller than the serum level. We thought that this hydroxyl radical scavenging effect might play some part also in this model. We may need a selection of rats in order to obtain more consistent values, or the use of much number of rats for clearer and significant results. Significant decrease in total protein and albumin in serum as well as significant increase in urinary protein and serum total cholesterol are described as nephrotic syndrome. Our 5/6 nephrectomized rats exhibited nephrotic syndrome. NZ-419 significantly inhibited the syndrome, and the effect seemed to be induced via NZ-419 having a protecting effect on the kidney. The hypoalbuminemia status is indicative of high oxidative stress, because albumin, a predominant serum protein with SH groups, is recognized as a reducing constituent in the body with a normalizing effect of the oxidative stress: its indicated anti-oxidant action which may be similar to that of NZ-419. So this normalizing effect on hypoalbuminemia is concerted with NZ-419 as anti-oxidants and could be one of mechanism by which NZ-419 acts.
Histological findings in 5/6 nephrectomized rats showed the incidence of extracapillary lesions and a glomerular sclerosis index increase in control rats, as is already known. NZ-419 inhibited the histological changes, but not significantly under our conditions. In order to confirm again whether the protecting effect on the kidney, not only of glomerular but also extracapillary regions we need more consistent or much number of rats.
Our results indicated that if an intrinsic antioxidant, NZ-419, is given as an extrinsic drug to rats with progressive CRF and CKD, until or during stages 3 and 4, the progression of damage can be inhibited. If we take its high-level safety 3) into consideration together with our results, NZ-419 can potentially be a therapeutic agent against progressive CRF at CKD stages 3 and 4.
